- Home
- PRTA vs CDNA Comparison
PRTA vs CDNA Comparison
Compare PRTA & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRTA | CDNA |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.9M | 712.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PRTA | CDNA |
|---|---|---|
| Price | $9.27 | $19.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $18.86 | ★ $26.67 |
| AVG Volume (30 Days) | 617.1K | ★ 800.2K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | $11,786,000.00 | ★ $357,998,000.00 |
| Revenue This Year | N/A | $14.11 |
| Revenue Next Year | $819.08 | $12.00 |
| P/E Ratio | ★ N/A | $15.79 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $4.32 | $10.96 |
| 52 Week High | $17.66 | $25.95 |
Technical Indicators
Market Signals| Indicator | PRTA | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 60.43 |
| Support Level | $9.69 | $19.21 |
| Resistance Level | $10.50 | $20.05 |
| Average True Range (ATR) | 0.57 | 0.89 |
| MACD | -0.16 | -0.07 |
| Stochastic Oscillator | 6.50 | 61.97 |
Price Performance
Historical ComparisonAbout PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.